Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
Vertex Pharmaceuticals Inc. closed $45.72 below its 52-week high ($510.64), which the company achieved on August 1st.
Demystifying Vertex Pharmaceuticals: Insights From 16 Analyst Reviews
The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...
Vertex Pharmaceuticals (VRTX) Gets a Hold from RBC Capital
In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), ...
Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors
This was the stock's second consecutive day of losses.
Looking Into Vertex Pharmaceuticals's Recent Short Interest
According to Benzinga Pro, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.15%, ...
bovnews4d
Why Did Barclays Give Vertex Pharmaceuticals Incorporated (VRTX) Stock Equal Weight Rating?
Barclays has recently reduced Vertex Pharmaceuticals Incorporated (VRTX) stock to Equal Weight rating, as announced on August 5, 2024, according to Finviz. Earlier, on June 27, 2024, Redburn Atlantic ...
Zacks.com on MSN6d
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know
Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day. This move outpaced the S&P 500's daily gain of 0.13%. At the same time, the Dow ...